Canada Life
ALLO icon

Canada Life’s Allogene Therapeutics ALLO Stock Holding History

Canada Life’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
75,949
+10,979
+17% +$24.1K ﹤0.01% 1622
2026
Q1 		$158K Buy
64,970
+14,019
+28% +$28.1K ﹤0.01% 1631
2025
Q4 		$69K Buy
50,951
+11,221
+28% +$14.8K ﹤0.01% 1759
2025
Q3 		$50K Buy
39,730
+8,519
+27% +$10.2K ﹤0.01% 1816
2025
Q2 		$35K Buy
31,211
+18,314
+142% +$24.3K ﹤0.01% 1854
2025
Q1 		$19K Sell
12,897
-7,528
-37% -$14.2K ﹤0.01% 1942
2024
Q4 		$44K Buy
20,425
+241
+1% +$594 ﹤0.01% 1898
2024
Q3 		$57K Sell
20,184
-3,908
-16% -$10.4K ﹤0.01% 1938
2024
Q2 		$56K Buy
24,092
+6,342
+36% +$18.7K ﹤0.01% 1955
2024
Q1 		$79K Buy
17,750
+8,162
+85% +$34.1K ﹤0.01% 1968
2023
Q4 		$31K Sell
9,588
-2,583
-21% -$7.33K ﹤0.01% 2070
2023
Q3 		$39K Hold
12,171
– – ﹤0.01% 2073
2023
Q2 		$61K Buy
12,171
+3,344
+38% +$18.1K ﹤0.01% 1983
2023
Q1 		$43K Buy
8,827
+1,826
+26% +$11.7K ﹤0.01% 2089
2022
Q4 		$44K Buy
7,001
+777
+12% +$7.19K ﹤0.01% 2094
2022
Q3 		$67K Buy
6,224
+484
+8% +$6.58K ﹤0.01% 2055
2022
Q2 		$66K Buy
5,740
+503
+10% +$4.46K ﹤0.01% 1994
2022
Q1 		$50K Buy
5,237
+450
+9% +$4.69K ﹤0.01% 2153
2021
Q4 		$72K Buy
4,787
+439
+10% +$7.75K ﹤0.01% 2081
2021
Q3 		$112K Hold
4,348
– – ﹤0.01% 2032
2021
Q2 		$113K Sell
4,348
-201
-4% -$5.73K ﹤0.01% 2056
2021
Q1 		$159K Buy
4,549
+935
+26% +$31.5K ﹤0.01% 2002
2020
Q4 		$91K Hold
3,614
– – ﹤0.01% 2134
2020
Q3 		$136K Hold
3,614
– – ﹤0.01% 1974
2020
Q2 		$154K Buy
3,614
+1,987
+122% +$71.9K ﹤0.01% 1958
2020
Q1 		$32K Hold
1,627
– – ﹤0.01% 2254
2019
Q4 		$42K Buy
+1,627
New +$44.8K ﹤0.01% 2317
2019
Q3 		– Sell
-3,067
Closed -$82K – 1151
2019
Q2 		$82K Buy
+3,067
New +$85.5K ﹤0.01% 2284

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Canada Life's ALLO Position: Q2 2026 in Review

Canada Life increased its Allogene Therapeutics (ALLO) stake by 17% in Q2 2026, buying an estimated $24.1K and bringing the position to 75,949 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #1622.

Canada Life first reported a position in ALLO in Q2 2019 and has held it in 28 quarters since. The position peaked at $159K in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Canada Life held 75,949 shares of Allogene Therapeutics worth $157K as of Q2 2026.
  • Canada Life bought 10,979 Allogene Therapeutics shares in Q2 2026, an estimated $24.1K.
  • Allogene Therapeutics made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1622 holding.
  • Canada Life first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Canada Life's Allogene Therapeutics position peaked at $159K in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.